R&D Trends

HitGen partners with Scripps Research Institute and Calibr

Monday, April 24, 2017

HitGen, a privately held biotech company focused on technology for effective and efficient small molecule drug discovery and development, announced a collaboration with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr). This collaboration is to discover and develop potential new therapies in areas of unmet clinical need, with an initial focus in oncology, regenerative medicine and virology.

[Read More]

NIH funds seven international centers of excellence for Malaria research

Monday, April 24, 2017

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, announced approximately $9 million in first-year funding, subject to availability, for seven malaria research centers around the world. The seven-year awards continue NIAID’s 2010 program that created the International Centers of Excellence for Malaria Research (ICEMRs) in regions where malaria is endemic. The awards fund three new and four existing centers that work in 14 countries in Africa, Asia and Latin America.

[Read More]

VolitionRX opens new R&D facility in Belgium

Monday, April 24, 2017

VolitionRx opened its new R&D facility. The new building will enable the company to increase capacity to carry out clinical trials and to expand its scientific team, thereby expediting the large number of trials underway. The new custom-designed facility comprises 9,000 square feet of office space and 10,000 square feet of high quality, purpose-built laboratory space. The facility is located in the Crealys Science Park, Isnes in the Wallonia region of Belgium, an area popular with other biotech and pharmaceutical companies.

[Read More]

Metrion Biosciences, Venomtech partner

Monday, April 24, 2017

Metrion Biosciences, a specialist ion channel CRO and drug discovery company, and Venomtech, a U.K. biotechnology company with a venom library, announced a collaboration agreement that will see the two companies combine their resources and expertise to search for novel ion channel modulators for use in drug discovery research.

[Read More]

Plasticell, Kings College London to collaborate in blood platelet substitute trials

Thursday, April 20, 2017

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has partnered with King’s College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells. The work is supported by a MedCity research grant which funds collaboration between leading SMEs and academics from London universities.

[Read More]

Cellular Dynamics International, Harvard Stem Cell Institute to collaborate

Thursday, April 20, 2017

Cellular Dynamics International (CDI), a FUJIFILM company and a developer and manufacturer of induced pluripotent stem cells (iPS), has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the University to its affiliated hospitals and the biomedical industry. The objective of the new partnership is to increase the availability of iPS cells and services to the HSCI network and the research community at large.

[Read More]

Parvus Therapeutics, Novartis partner to treat type 1 diabetes

Thursday, April 20, 2017

Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility complexes (pMHCs) that alter the behavior of disease-causing T lymphocytes. Navacims are the first biopharmaceuticals to demonstrate in preclinical models the ability to restore immune tolerance in a disease-specific manner through in vivo formation and expansion of regulatory T-cells (T-regs) without causing general immune suppression.

[Read More]

CRISPR Therapeutics, Casebia Therapeutics partner with StrideBio

Tuesday, April 18, 2017

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer for developing CRISPR-based therapeutics in select disease areas, have signed a collaboration agreement with StrideBio, a U.S.-based company developing novel AAV vectors for in vivo gene delivery applications.

[Read More]